Medi Caps Ltd

Medi Caps, a microcap pharmaceutical company, has reported positive financial results for the quarter ending September 2024. The company's operating cash flow has been the highest in the last three years, with a significant improvement in its score. Net sales and profit after tax have also shown a positive trend, leading to an increase in earnings per share. MarketsMOJO has given a 'Sell' call for the company's stock based on these results.

Medi Caps, a microcap pharmaceutical company, reported negative financial results for the quarter ending March 2024. The company's Debtors Turnover Ratio has been consistently falling and Net Sales have declined by -9.3%. With a Strong Sell rating from MarketsMOJO, investors should carefully assess the company's performance before making any investment decisions.

Medi Caps, a microcap pharmaceutical company, reported a negative performance in the quarter ending March 2024, with a score of -11. This is an improvement from the previous quarter's score of -17. The company's financials have been declining, with a significant decrease in PBT and PAT, and a decrease in net sales. Investors should consider these numbers before making any investment decisions.

Medi Caps, a microcap pharmaceutical company, has reported a negative performance in the quarter ending December 2023, with a decrease in Profit After Tax and Net Sales. The company's Debtors Turnover Ratio and Cash and Cash Equivalents have also been declining, indicating potential financial challenges. Investors should carefully evaluate before investing.

Medi Caps, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs.63.49 on January 30, 2024. Despite a 'Sell' rating from MarketsMOJO, the company's performance is in line with the sector and has shown consecutive gains, outperforming the market. With a strong performance over the past year and positive market indicators, Medi Caps has the potential for growth and is a company to watch out for.

Medi Caps, a microcap pharmaceutical company, has been making headlines as its stock price reached a 52-week high on January 9th, 2024. The stock has been outperforming the sector by 13.59% and has seen a significant increase of 15.66% in the last two days. Despite a 'Sell' call from MarketsMOJO, the stock's performance and volatility suggest potential growth for investors.

Medi Caps, a microcap pharmaceutical company, reported a decline of 5.49% in net sales for the quarter ended September 2023, but a significant growth of 110.81% in consolidated net profit. However, MarketsMOJO has given a 'Strong Sell' call for the company's stock. Despite some positive improvements, the overall financial performance has been deemed as very negative, with declining net sales and profit before tax, decreasing operating cash flow, and deteriorating short-term liquidity.